Drug delivery to the inner ear: Strategies and their therapeutic implications for sensorineural hearing loss

Current Drug Delivery

Volumn 9, Issue 3, 2012, Pages 231-242

  Rivera, Teresa ^a,b   Sanz, Lorena ^a,b   Camarero, Guadalupe ^b,c   Varela Nieto, Isabel ^b,c,d  

^a HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Cochleostomy; Intracochlear; Intratympanic; Local therapy; Microcathether; Mutant mice; Osmotic pump; Round window; Sensorineural deafness

Indexed keywords

AM 111; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BUMETANIDE; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; ERYTHROMYCIN; FUROSEMIDE; GLUCOCORTICOID; HYDROCORTISONE; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

DRUG ADMINISTRATION; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE MEDIATED INNER EAR DISEASE; INNER EAR; INNER EAR DISEASE; INTRACOCHLEAR DRUG ADMINISTRATION; INTRATYMPANIC DRUG ADMINISTRATION; MENIERE DISEASE; METABOLIC DISORDER; NOISE INDUCED HEARING LOSS; OTOTOXICITY; PERCEPTION DEAFNESS; PRESBYACUSIS; PRIORITY JOURNAL; REVIEW; SUDDEN DEAFNESS;

EID: 84860538606     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112800389098     Document Type: Review

References (126)

1. World Health organization. http://www.who.int/topics/deafness/en/ [Accessed June 16, 2011]
2. Promenade the round cochlea. http://www.neuroreille.com/promenade/english/corti/fcorti.htm [Accesed April 28, 2011]
3. Dror, A.A.; Avraham, K.B. Hearing loss: mechanisms revealed by genetics and cell biology. Annu. Rev. Genet., 2009, 43, 411-437.
4. National institutes of Health. National Institute of Deafness and other Communications Disorders. http://www.nidcd.nih.gov/ [Accessed May 12, 2011]
5. Jongkamonwiwat, N.; Zine, A.; Rivolta, M.N. Stem cell based therapy in the inner ear: appropriate donor cell types and routes for transplantation. Curr. Drug. Targets., 2010, 11(7), 888-897.
6. Rivolta, M.N. Stem cells and cell lines from the human auditory organ: applications, hurdles and bottlenecks in the development of regenerative therapies for deafness. Drug. Discov. Today, 2010, 15(7-8), 283-286.
7. Sanchez-Calderon, H.; Milo, M.; Leon, Y.; Varela-Nieto, I. A network of growth and transcription factors controls neuronal differentation and survival in the developing ear. Int. J. Dev. Biol., 2007, 51(6-7), 557-570.
8. Magariños, M.; Aburto, M.R.; Sánchez-Calderón, H.; Muñoz-Agudo, C.; Rapp, U.R.; Varela-Nieto, I. RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development. PLoS One, 2010, 5(12), e14435.
9. Murillo-Cuesta, S.; Contreras, J.; Cediel, R.; Varela-Nieto, I. Comparison of different aminoglycoside antibiotic treatments to refine ototoxicity studies in adult mice. Lab. Anim., 2010, 44(2), 124-131.
10. Murillo-Cuesta, S.; García-Alcántara, F.; Vacas, E.; Sistiaga, J.A.; Camarero, G.; Varela-Nieto, I.; Rivera, T. Direct drug application to the round windows: a comparative study of ototoxicity in rats. Otolaryngol. Head Neck Surg., 2009, 14(5), 584-590.
11. Henley, C.M.; Schacht, J. Pharmacokinetics of aminoglycoside antibiotics in blood, inner ear fluids and tissues and their relation-ship to ototoxicity. Audiology, 1998, 27,137-146.
12. Schacht, J. Biochemical basis of aminoglycoside ototoxicity. Otol. Clin. North. Am., 1993, 26, 843-854.
13. McGhan, L.J.; Merchant, S.N. Erytromycin ototoxicity. Otol. Neurotol., 2003, 24(4),701-702.
14. Ikeda, K.; Oshima, T.; Hidaka, H.; Takasaka, T. Molecular and clinical implications of loop diuretic ototoxicity. Hear. Res., 1997; 107 (1-2), 1-8.
15. Jung, T.T.; Rhee, C.H.; Lee, C.S.; Park, Y.S.; Choi, D.C. Ototoxicity of salicylate, nonsteroidal anti-inflammatory drugs and quinine. Otol. Clin. North Am., 1993, 26,787-807.
16. Rybak, L.P. Mechanisms of cisplatin ototoxicity and progress in otoprotection. Curr. Opin. Otolaryngol. Head Neck Surg., 2007, 15, 364-369.
17. Vyskocil, A.; Leroux, T.; Truchon, G.; Lemay, F.; Gagnon, F.; Gendron, M.; Viau, C. Ototoxicity of trichloroethylene in concentrations relevant for the working environment. Hum. Exp. Toxicol., 2008, 27(3), 195-200.
18. Tawackoli, W.; Chen, G.D.; Fechter, L.D. Disruption of cochlear potentials by chemical asphyxiants. Cyanide and carbon monoxide. Neurotoxicol. Teratol., 2001, 23(2), 157-165.
19. Karkalapudi, V.; Sawyer, R.; Staecker, H. The effect of Diabetes on Sensorineural Hearing Loss. Otol. Neurotol., 2003, 24, 382-386.
20. García-Berrocal, J.R.; Ramírez-Camacho, R. Immune response and immunopathology of the inner ear: an update. J. Laryngol. Otol., 2000, 114, 101-107.
21. García-Berrocal, J.R.; Ramírez-Camacho, R.; Lobo, D.; Trinidad, A.; Verdaguer, J.M. Adverse effects of glucocorticoid therapy for inner ear disorders. Otorhinolaryngol. Relat. Spec., 2008, 70(4), 271-274.
22. Plaza G.; Durio, E.; Herraiz, C.; Rivera, T.; García-Berrocal, J.R. Consensus on diagnosis and treatment of sudden hearing loss. Acta Otorrinolaringol. Esp., 2011, 62, 144-157.
23. Rauch, S.D. Clinical practice. Idiopathic sudden sensorineural hearing loss. N. Engl. J. Med., 2008, 359, 833-840.
24. Schreiber, B.E.; Agrup, C.; Haskard, D.O.; Luxon, L.M. Sudden sensorineural hearing loss. Lancet, 2010, 375, 1203-1211.
25. Merchant, S.N.; Durand, M.L.; Adams, J.C. Sudden deafness: is it vial?. O.R.L. J. Otorhinolaryngol. Relat. Spec., 2008, 70, 52-56.
26. García-Berrocal, J.R.; Ramirez-Camacho, R.; Portero, F.; Vargas, J.A. Role of viral and Mycoplasma pneumoniae infection in idiopathic sudden sensorineural hearing loss. Acta Otolaryngol., 2000, 835-859.
27. Zadeh, M.H.; Storper, I.S.; Spitzer, J.B. Diagnosis and treatment of sudden-onset sensorineural hearing loss: a study of 51 patients. Otolaryngol. Head Neck Surg., 2003, 128, 92-98.
28. Capaccio, P.; Cuccarini, V.; Ottaviani, F.; Fracchiolla, N.S.; Bossi, A.; Pignataro, L. Prothrombotic gene mutations in patients with suddensensorineural hearing loss and cardiovascular thrombotic disease. Ann. Otol. Rhinol. Laryngol., 2009, 118, 205-210.
29. Marcucci, R.; Alessandrello Liotta, A.; Cellai, A.P.; Rogolino, A.; Berloco, P.; Leprini, E.; Pagnini, P.; Abbate, R.; Prisco, D. Cardio-vascular and thrombophilic risk factors for idiopathic sudden senorineural hearing loss. J. Thromb. Haemost., 2005, 3, 929-934.
30. Echarri, R.M.; Rivera, T.; Mate, M.A.; Cobeta, I. Sudden hearing loss: effectiveness of a therapeutic protocol. Acta Otorrinolaringol. Esp., 2000, 51, 490-494.
31. Weber, P.C. Sudden sensorineural hearing loss. In: UpTodate, Dechler DJ (Ed.), UpToDate, Waltham, MA, 2009.
32. Chau J K.; Lin, J.R.; Atashband, S.; Irvine, R.A.; Westerberg, B.D. Systematic review of the evidence for the etiology of adult sudden sensorineural hearing loss. Laryngoscope, 2010, 120, 1011-1021.
33. Garcia-Berrocal, J.R.; Trinidad, A.; Ramirez-Camacho, R.; Verdaguer, J.M.; Ibañez, A. Immunologic work-up study for inner ear disorders: looking for a rational strategy. Acta Otolaryngol., 2005, 125, 814-818.
34. Nakagawa, T.; Sakamoto, T.; Hiraumi, H; Kikkawa, Y.S.; Yamamoto, N.; Hamaguchi, K.; Ono, K.; Yamamoto, M.; Tabata, Y.; Teramukai, S.; Tanaka, S.; Tada, H.; Onodera, R.; Yonezawa, A.; Inui, K.; Ito, J. Topical insulin-like growth factor 1 treatment using gelatin hydrogels for glucocorticoid-resistant sudden hearing loss: a prospective clinical trial. B.M.C. Med., 2010, 8, 76.
35. Varela-Nieto, I.; Hartl, M.; Gorospe, I.; León, Y. Anti-apoptotic actions of insulin-like growth factors: lessons from development and implications in neoplastic cell transformation. Curr. Pharm. Des., 2007, 13(7),687-703.
36. Fleissner, F.; Thum, T. The IGF-1 receptor as a therapeutic target to improve endothelial progenitor cell function. Mol. Med., 2008, 14(5-6), 235-237.
37. Ohlemiller, K.K. Recent findings and emerging questions in cochlear noise injury. Hear Res., 2008, 245 (1-2), 5-17.
38. Konings, A.; Van Laer, L.; Van Camp, G. Genetic studies on noise-induced hearing loss: a review. Ear Hear., 2009, 30(2), 151-159.
39. Dobie, R.A. Separating noise-induced from age-related hearing loss. West J. Med., 1994, 160, 564-565.
40. McShane, D.P.; Hyde, M.L.; Finkelstein, D.M.; Alberti, P.W. Unilateral otosclerosis and noise-induced occupational hearing loss. Clin. Otolaryngol., 1991, 16, 70-75.
41. Shemesh, Z.; Attias, J.; Oman, M.; Shapira, N.; Shahar, A. Vitamin B12 deficiency in patients with chronic-tinnitus and noise-induced hearing loss. Am. J. Otolaryngol., 1993, 14, 94-99.
42. Yamane, H.; Nakai, Y.; Takayama, M.; Nakagawa, T.; Kojima, A. Appearance of free radicals in the guinea pig inner ear after noise-induced acoustic trauma. Eur. Arch. Otorhinolaringol., 1995, 252, 504-508.
43. Yamane, H.; Nakai, Y.; Takayama, M.; Konishi, K.; Nakagawa, T.; Shibata, S.; Kato, A.; Sunami, K.; Kawakatsu, C. The emergence of free radicals after acoustic trauma and strial blood flow. Acta Otolaryngol. Suppl. (Stockh)., 1995, 519, 87-92.
44. Prell, C.G.; Yamashita, D.; Minami, S.B.; Yamasoba, T.; Miller, J.M. Mechanisms of noise-induced hearing loss indicate multiple methods of prevention. Hear Res., 2007, 226(1-2), 22-43.
45. Heinrich, U.R.; Feltens, R. Mechanisms underlying noise-induced hearing loss. Drug Discovery today: disease mechanisms, 2006, 3, 131-135.
46. Cobo, P.; Murillo-Cuesta, S.; Cediel, R.; Moreno, A.; Lorenzo-García, P.; Varela-Nieto, I. Appl. Acoustic., 2009, 70(8), 1034.
47. Ohlemiller, K.K. Age-related hearing loss: the status of Schuknecht́s tipology. Curr. Opin. Otolaryngol. Head Neck Surg., 2004, 12, 439-443.
48. Schuknecht, H.F. Presbycusis. Laryngoscope, 1995, 65, 402-419.
49. Schuknecht, H.F.; Gacek, M.R. Cochlear pathology in presbycusis. Ann. Otol. Rhinol. Laryngol., 1993, 102, 1-16.
50. Scholtz, A.W.; Kammen-Jolly, K.; Felder, E.; Hussl, B.; Rask-Andersen, H.; Scrott-Fisher, A. Selective aspects of human pathology in high-tone hearing loss of the aging inner ear. Hear Res., 2001, 157, 77-86.
51. Van Eyken, E.; Van Laer, L.; Fransen, E.; Topsakal, V.; Hendrickx, J.J.; Demeester, K.; Van de Heyning, P.; Mäki-Torkko, E.; Hannula, S.; Sorri, M.; Jensen, M.; Parving, A.; Bille, M.; Baur, M.; Pfister, M.; Bonaconsa, A.; Mazzoli, M.; Orzan, E.; Espeso, A.; Stephens, D.; Verbruggen, K.; Huyghe, J.; Dhooge, I.; Huygen, P.; Kremer, H.; Cremers, C.; Kunst, S.; Manninen, M.; Pyykkö, I.; Rajkowska, E.; Pawelczyk, M.; Sliwinska-Kowalska, M.; Steffens, M.; Wienker, T.; Van Camp, G. The contribution of GJB2 (conexin 26) 35delG to age-related hearing impairment and noise-induced hearing loss. Otol. Neurotol., 2007, 28(7), 970-975.
52. Johnson, K.R.; Enway, L.C.; Cook, S.A.; Willott, J.F.; Zheng, Q.Y. A major gene affecting age-related hearing loss in C57BL/6J mice. Hear Res., 1997, 114, 83-92.
53. Bolz, H.; Brederlow, B.; Ramirez, A.; Bryda, E.C.; Kutsche, K.; Nothwang, H.G.; Seeliger, M.; C-Salcedó Cabrera, M.; Vila, M.C.; Molina, O.P.; Gal, A.; Kubisch, C. Mutation of CDH23 encoding a new member of the cadherin gene family, causes Usher syndrome type 1D. Nat. Gennet., 2001, 27, 108-112.
54. Fishel-Ghodsian, N. Mitochondrial deafness. Ear. Hear., 2003, 24, 303-313.
55. Murillo-Cuesta, S.; Contreras, J.; Zurita, E.; Cediel, R.; Cantero, M.; Varela-Nieto, I.; Montoliu, L. Melanin precursors prevent premature age-related and noise-induced hearing loss albino mice. Pigment. Cell. Melanoma Res., 2010, 23(1), 72-83.
56. Riquelme, R.; Cediel, R.; Contreras, J.; la Rosa, L.; Murillo-Cuesta, S.; Hernández-Sánchez, C.; Zubeldia, J.M.; Cerdan, S.; Varela-Nieto, I. A comparative study of age-related hearing loss in wild type and insuline-like growth factor 1 deficient mice. Front. Neuroanat., 2010, 4, 27.
57. Hardisty-Hughes, R.E.; Parker, A.; Brown, S.D. A hearing and vestibular phenotyping pipeline to identify mouse mutants with hearing impairment. Nat. Protoc., 2010, 5 (1), 177-190.
58. Lang, H.; Schulte, B.A; Schmiedt, R.A. Effects of chronic furosemide treatment and age on cell division in the adult gerbil inner ear. J. Assoc. Res. Otolaryngol., 2003, 4, 164-175.
59. Seidman, M.D. Effects of dietary restriction and antioxidants on presbycusis. Laryngosocpe, 2000, 110, 727-738.
60. Kuts, J.W. Jr. The dizzy patient. Med. Clin. North Am., 2010, 94(5), 989-1002.
61. Salt, A.N. Pharmacokinetics of drug entry into cochlear fluids. Volta Rev., 2005,105,277-298.
62. Suckfuell, M.; Canis, M.; Strieth, S.; Scherer, H.; Haisch, A. Intra-tympanic treatment of acute acoustic trauma with a cell-permeable JNK ligand: a prospective randomized phase I/II study. Acta Otolaryngol., 2007, 127, 938-942.
63. Gopen, Q.; Rosowski, J.; Merchant, S. Anatomy of the normal human cochlear aqueduct with functional implications. Hear Res., 1997, 107, 9-22.
64. Juhn, S.; Hamaguchi, Y.; Goycoolea, M. Review of round window membrane permeability. Acta Otolaryngol. Suppl., 1989, 457,43-45.
65. Salt, A.N. Simulation of methods for drug delivery to the cochlear fluids. Adv. Otorhinolaryngol., 2002, 59, 140-148.
66. Shepherd, R.; Colreavy, M. Surface microsuture of the perylymphatic space: implications of cochlear implants and cell or drug based therapies. Arch. Otolaryngol., 2004, 123, 518-523.
67. Salt, A.N.; Hale, S.A. Longitudinal distribution of drugs in perilymph assessed by cochlear action potentials, 28th Mid Winter Research Meeting of the JARO, 2005.
68. Ohyama, K.; Salt, A.N.; Thalmann, R. Volume flow Rate of perylymph in the guinea pig cochlea. Hear Res., 1988, 35, 119-130.
69. Salt, A.N.; Plontke, S.K.R. Local inner-ear drug delivery and pharmacokinetics. Drug Discov. Today, 2005, 10, 1299-1306.
70. Ersner, M.S.; Spiegel, E.A.; Alexander, M.H. Transtympanic injection of anesthetics for the treatment of Ménière's syndrome. AMA. Arch. Otolaryngol., 1951, 54, 43-52.
71. Schuknecht, H.F. Ablation therapy for the relief of Ménière's disease. Laryngoscope, 1956, 66, 859-870.
72. Blakley, B.W. Clinical forum: a review of intratympanic therapy. Am. J. Otol., 1997, 18, 520-526.
73. Carey, J. Intratympanic gentamicin for the treatment of Meniere's disease and other forms of peripheral vertigo. Otolaryngol. Clin. North Am., 2004, 37, 1075-1090.
74. Richardson, R.; Noushi, F.; Oleary, S. Inner ear therapy for neural preservation. Audiol. Neurootol., 2006, 11(6), 343-56.
75. Barrs, D.M. Intratympanic corticosteroids for Meniere's disease and vertigo. Otolaryngol. Clin. North Am., 2004, 37, 955-972.
76. Rauch, S.D. Intratympanic steroids for sensorineural hearing loss. Otolaryngol. Clin. North Am., 2004, 37, 1061 1074.
77. Haynes, D.S.; O'Malley, M.; Cohen, S.; Watford, K.; Labadie, R.F. Intratympanic dexamethasone for sudden sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 2007, 117, 3-15.
78. Plontke, S.K.; Löwenheim, H.; Mertens, J.; Engel, C.; Meisner, C.; Weidner, A.; Zimmermann, R.; Preyer, S.; Koitschev, A.; Zenner, H.P. Randomized, double blind, placebo controlled trial on the safety and efficacy of continuous intratympanic dexamethasone delivered via a round window catheter for severe to profound sudden idiopathic sensorineural hearing loss after failure of systemic therapy. Laryngoscope, 2009, 119, 359-369.
79. Light, J.P.; Silverstein, H. Transtympanic perfusion: indications and limitations. Curr. Opin. Otolaryngol. Head Neck Surg., 2004, 12, 378-383.
80. Sakata, E.; Ito, Y.; Itoh, A. Clinical experiences of steroid targeting therapy to inner ear for control of tinnitus. Int. Tinnitus J., 1997, 3, 117-121.
81. Silverstein, H.; Silverstein, H.; Choo, D.; Rosenberg, S.I.; Kuhn, J.; Seidman, M.; Stein, I. Intratympanic steroid treatment of inner ear disease and tinnitus. Ear Nose Troath J., 1996, 75, 468-471.
82. Lin, J.; Juhn, S.K.; Adams, G.L.; Giebink, G.S.; Kim, Y. Dexamethasone inhibits mucous glycoprotein secretion via a phospholipase A2 dependent mechanism in cultured chinchilla middle ear epithelial cells. Acta Otolaryngol., 1997, 117 (3), 406-413.
83. Arriaga, M.A.; Goldman, S. Hearing results of intratympanic steroid treatment of endolymphatic hydrops. Laryngoscope, 1998, 108(11), 1682-1685.
84. Sennaroglu, L.; Sennaroglu, G.; Gursel, B.; Dini, F.M. Intra-tympanic dexamethasone, intratympanic gentamicin, and endolym-phatic sac surgery for intractable vertigo in Meniere's disease. Oto-laryngol. Head Neck Surg., 2002, 127(5), 491-492.
85. Parnes, L.S.; Sun, A.H.; Freeman, D. J. Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope, 1999, 109 (7), 1-17.
86. McCormick, D.P.; Saeed, K.; Uchida, T.; Baldwin, C.D.; Deskin, R.; Lett-Brown, M.A.; Heikkinen, T.; Chonmaitree, T. Middle ear fluid histamine and leukotrlene B4 in acute otitis media: effect of antlhistamine or corticosteroid treatment. Int. J. Pediatr. Otorhinolaryngol., 2003, 67 (3), 221-230.
87. Johnson, K.R.; Enway, L.C.; Cook, S.A.; Willott, J.F.; Zheng, Q.Y. A major gene affecting age-related hearing loss in C57BL/6J mice. Hear Res., 1997, 114, 83-92.
88. Banerjee, A.; Parnes, L.S. The biology of intratympanic drug administration and pharmacodynamics of round window drug absorption. Otolaryngol. Clin. North Am., 2004, 37, 1035-1051.
89. McCall, A.A.; Swan, E.E.; Borenstein, J.T.; Sewell, W.F.; Kujawa, S.G.; McKenna, M.J. Drug delivery for treatment of inner ear disease: current state of knowledge. Ear Hear., 2010, 31(2), 156-165.
90. Plontke, S.K.R.; Wood, A.W.; Salt, A.N. Analysis of gentamicin kinetics in fluids of the inner ear with round window administration. Otol. Neurotol., 2002, 23, 967-974.
91. Seidman, M.D. Glutamate antagonists, steroids, and antioxidants as therapeutic options for hearing loss and tinnitus and the use of an inner ear drug delivery system. Int. Tinnitus J., 1998, 4,148-154.
92. Seidman, M.D.; van de Water, T.R. Pharmacologic manipulation of the labyrinth with novel and traditional agents delivered to the inner ear. Ear Nose Throat J., 2003, 82, 276-300.
93. Silverstein, H. Use of a new device, the microwick, to deliver medication to the inner ear. Ear Nose Throat J., 1999, 78, 595-600.
94. Hillman, T.M.; Arriaga, M.A.; Chen, D.A. Intratympanic steroids: do they acutely improve hearing in cases of cochlear hydrops?. Laryngoscope, 2003, 113, 1903-1907.
95. Blakley, B.W. Update on intratympanic gentamicin for meniere's disease. Laryngoscope, 2000, 110, 236-240.
96. Hoffer, M.; Balough, B.; Henderson, J.; DeCicco, M.; Wester, D.; O'Leary, M.; Kopke, R. Use of sustained release vehicles in the treatment of Meniere's disease. Otolaryngol. Clin. North Am., 1997, 30, 1159-1166.
97. Iwai, K.; Nakagawa, T.; Endo, T.; Matsuoka, Y.; Kita, T.; Kim, S.; Tabata, Y.; Ito, J. Cochlear protection by local insulin-like growth factor-1 application using biodegradable hydrogel. Laryngoscope, 2006, 116, 529-533.
98. Ito, J.; Endo, T.; Nakagawa, T.; Kita, T.; Kim, T.S.; Iguchi, F.A new method for drug application to the inner ear. O.R.L. J. Otorhinolaryngol. Relat. Spec., 2005, 67, 272-275.
99. Endo, T.; Nakagawa, T.; Kita, T.; Iguchi, F.; Kim, T.S.; Tamura, T.; Iwai, K.; Tabata, Y.; Ito, J. Novel strategy for treatment of inner ears using a biodegradable gel. Laryngoscope, 2005, 115, 2016-2020.
100. Pasic, T.; EW, R. Rapid changes in cochlear nucleus cell size following blockage of auditory nerve electrical activity in gerbils. J. Comp. Neurol., 1989, 283, 474-480.
101. Arnold, W.; Senn, P.; Hennig, M.; Michaelis, C.; Deingruber, K.; Scheler, R.; Steinhoff, H.J.; Riphagen, F.; Lamm, K. Novel slow-and fast-type drug release roundwindow microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiol. Neurootol., 2005, 10, 53-63.
102. Praetorius, M.; Limberger, A.; Muller, M.; Lehner, R.; Schick, B.; Zenner, H.; Plinkert, P.; Knipper, M. A novel microperfusion system for the long term local supply of drugs to the inner ear: implantation and function in the rat model. Audiol. Neurootol., 2001, 6, 250-258.
103. Tamura, T.; Kita, T.; Nakagawa, T.; Endo, T.; Kim, T.S.; Ishihara, T.; Mizushima, Y.; Higaki, M.; Ito, J. Drug delivery to the cochlea using PLGA nanoparticles. Laryngoscope, 2005, 115, 2000-2005.
104. Ge, X.; Jackson, R.L.; Liu, J.; Harper, E.A.; Hoffer, M.E.; Wassel, R.A.; Dormer, K.J.; Kopke, R.D.; Balough, B.J. Distribution of PLGA nanoparticles in chinchilla cochleae. Otolaryngol. Head Neck Surg., 2007, 137, 619-623.
105. Brown, J.N.; Miller, J.M.; Altschuler, R.A.; Nuttall, A.L. Osmotic pump implant for chronic infusion of drugs into the inner ear. Hear Res., 1993, 70, 167-172.
106. Theeuwes, F.; Yum, S.I. Principles of the design and operation of generic osmotic pumps for the delivery of semisolid or liquid drug formulations. Ann. Biomed. Eng., 1976, 4, 343-353.
107. Lehner, R.; Brugger, H.; Maassen, M.M.; Zenner, H. A totally implantable drug delivery system for local therapy of the middle and inner ear. Ear Nose Throat J., 1997, 76, 567-570.
108. Salt, A.N.; Hale, S.A.; Plontke, S.K. Perilymph sampling from the cochlear apex: a reliable method to obtain higher purity perilymph samples from the scala tympani. J. Neurosci. Methods, 2006, 153, 121-129.
109. Salt, A.N.; Ma, Y. Quantification of solute entry into cochlear perilymph through the round window membrane. Hear Res., 2001, 154, 88-97.
110. De Ceulaer, G.; Johnson, S.; Yperman, M.; Daemers, K.; Offeciers, F.E.; O'Donoghue, G.M.; Govaerts, P.J. Long-term evaluation of the effect of intracochlearsteroid deposition on electrode impedance in cochlear implant patients. Otol. Neurotol., 2003, 24, 769-774.
111. Paasche, G.; Bockel, F.; Tasche, C.; Lesinski-Schiedat, A.; Lenarz, T. Changes of postoperative impedances in cochlear implant patients: the short-term effects of modified electrode surfaces and in- tracochlear corticosteroids. Otol. Neurotol., 2006, 27, 639-647.
112. Praetorius, M.; Baker, K.; Brough, D.E.; Plinkert, P.; Staecker, H. Pharmacodynamics of adenovector distribution within the inner ear tissues of the mouse. Hear Res., 2007, 227, 53-58.
113. Oestreicher, E.; Arnold, W.; Ehrenberger, K.; Felix, D. New approaches for inner ear therapy with glutamate receptors. Acta Otolaryngol., 1999, 119, 174-178.
114. Stover, T.; Yagi, M.; Raphael, Y. Cochlear gene transfer: round window versus cochleostomy inoculation. Hear Res., 1999, 136, 124-130.
115. Salt, A.N.; Sirjani, D.B.; Hartsock, J.J.; Gill, R.M.; Plontke, S.K. Marker retention in the cochlea following injections through the round window membrane. Hear Res., 2007, 232, 78-86.
116. Richardson, R.T.; Wise, A.; O'Leary, S.; Hardman, J.; Casley, D.; Clark, G. Tracing neurotrophin-3 diffusion and uptake in the guinea pig cochlea. Hear Res., 2004, 198, 25-35.
117. Carvalho, G.J.; Lalwani, A.K. The effect of cochleostomy and intracochlear infusion on auditory brain stem response threshold in the guinea pig. Am. J. Otol., 1999, 20, 87-90.
118. Eshraghi, A.A.; Adil, E.; He, J.; Graves, R.; Balkany, T.J.; van de Water, T.R. Local dexamethasone therapy conserves hearing in an animal model of electrodeinsertion trauma-induced hearing loss. Otol. Neurotol., 2007, 28, 842-849.
119. Wang, J.; Ladrech, S.; Pujol, R.; Brabet, P.; van de Water, T.R.; Puel, J.L. Caspase inhibitors, but not c-jun NH2-terminal kinase inhibitor treatment, prevent cisplatin-induced hearing loss. Cancer Res., 2004, 64, 9217-9224.
120. Schindler, R.A.; Gladstone, H.B.; Scott, N.; Hradek, G.T.; Williams, H.; Shah, S.B. Enhanced preservation of the auditory nerve following cochlear perfusion with nerve growth factor. Am. J. Otol., 1995, 16, 304-309.
121. Wang, J.; Pignol, B.; Chabrier, P.E.; Saido, T.; Lloyd, R.; Tang, Y.; Lenoir, Y.M.; Puel, J.L. A novel dual inhibitor of calpains and lipid peroxidation (bn82270) rescues the cochlea from sound trauma. Neuropharmacology, 2007, 52, 1426-1437.
122. Pettingill, L.N.; Richardson, R.T.; Wise, A.K.; O'Leary, S.; Shepherd, R.K. Neurotrophic factors and neural prostheses: potential clinical applications based upon findings in the auditory system. I.E.E.E. Trans. Biomed. Eng., 2007, 54, 1138-1148.
123. Duan, M.L.; Ulfendahl, M.; Laurell, G.; Counter, A.S.; Pyykko, I.; Borg, E.; Rosenhall, U. Protection and treatment of sensorineural hearing disorders caused by exogenous factors: experimental findings and potential clinical application. Hear Res., 2002, 169, 169-178.
124. Hochmair, I.; Nopp, P.; Jolly, C.N.; Schmidt, M.; Schober, H.; Garnham, C.; Anderson, I. Med-el cochlear implants: state of the art and a glimpse into the future. Trends Amplif., 2006, 10, 201-220.
125. Kingma G.G.; Miller J.M.; Myers M.W. Chronic drug infusion into the Scala tympani if the guinea pig cochlea. J. Neurosci. Methods, 1992, 45, 127-134.
126. Leary Swan, E.E.; Fiering J.O.; Sewell W.F.; Kujawa S.G.; McKenna M.J.; Borenstein J.T.; Mescher M.J. Microfabricated Components For Fully Implantable Microfluidic Drug Delivery To The Inner Ear, 34th Annual Meeting and Exhibition of the Con-trolled Release Society, Long Beach, CA, 2007.